We can help you address your key challenges in iPSC manufacturing and convert them into opportunities. Whether it is iPSC reprogramming or differentiation under cGMP, process control and characterization or efficient scale-up, we have a tailored solution.
As the manufacturers of the world’s first reported GMP iPSC bank, we have extensive experience in cGMP pluripotent stem cell generation and banking.
We provide a full range of iPSC manufacturing services tailored to your needs, to help you achieve scalable production in a cGMP setting.
We have the expertise to reprogram many different cell types such as human peripheral blood mononuclear cells (PBMCs), dermal fibroblasts, CD34+ hematopoietic progenitors and T cells.
Non-viral 4D-Nucleofector™ Transfection Technology is a key integral part for the reprogramming of cGMP grade iPSCs. With our cGMP iPSC manufacturing platform using the L7 cell culture system, you can rely on a proven, established process.
We have successfully generated specialized cells from human pluripotent stem cells in both standard 2D cell culture system and in a computer-controlled 3D bioreactor.
Use the form below to schedule a meeting with our iPSCs manufacturing experts.
Lonza provides the information contained herein “as-is” and without warranty, either express or implied. Customers are encouraged to consider intellectual property rights associated with iPSC processes on their own and Lonza makes no representations or warranties as to whether a particular process, method, or product described herein infringes others’ intellectual property.